ags cells

Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.

Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis.

Ursolic acid (Prunol) is a natural product, a pentacyclic triterpene carboxylic acid extracted from Rhododendron caprifolium. Ursolic acid has anti-tumor, anti-inflammatory, anti-bacterial and hypoglycemic activities.

GSK126 (GSK2816126A) is a excellently specific EZH2 methyltransferase inhibitor ( IC50=9.9 nM).

Danshenxinkun A is a natural product isolated from Salvia miltiorrhiza (Tanshen) exhibiting neuraminidase inhibitory activity with an IC50 of 39.5 mg/L.

Ibuprofen (Advil) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes.

12-O-deacetyl-phomoxanthone is a sodium-calcium exchanger NCX1 antiporter agonist with IC50 = 5.2µM for gastric cancer AGS cells.

KRASG12D-IN-3-D3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (T206049) (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.

YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits the growth of GEAC cells (including radioresistant tumors) and suppresses tumor proliferation, metastasis, and cancer stem cells.

Antitumor agent-155 (Compound 13) inhibits microtubule polymerization and induces autophagy and apoptosis. It exhibits cytotoxicity against HCT116, A549, AGS, and SK-MES-1 cells, with IC50 values of 0.227, 0.253, 0.574, and 0.423 μM, respectively.

PROTACpan-KRAS degrader-1 is a pan-KRAS PROTAC degrader that targets multiple KRAS mutants, including G12D, G12C, G12V, and G13D. It effectively degrades the KRAS mutant (G12D) in AGS cells, with a DC50 of 1.1 nM and a Dmax of 95%. This compound can be used in studies of diseases caused by KRAS mutations or amplifications, particularly in cancers such as breast, bladder, and gastric cancer.

KB-15 is a STAT3 inhibitor exhibiting significant antiproliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). It exerts its antitumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular reactive oxygen species (ROS) accumulation. Additionally, KB-15 induces G0/G1 phase cell cycle arrest and apoptosis while hindering colony formation and migration in gastric cancer cells. In the BGC-823 subcutaneous xenograft model, KB-15 demonstrates excellent antitumor efficacy.

CQ3196 is an oral RIOK2 inhibitor with a Kd value of 14 nM. It effectively suppresses the ATPase activity of RIOK2, showing an IC50 value of 72 nM. CQ3196 also impedes cell proliferation and colony formation in gastric cancer cell lines, inducing apoptosis (apoptosis) in HGC-27 and AGS cells. Furthermore, CQ3196 inhibits downstream signaling pathways of RIOK2, reducing mTOR and AKT phosphorylation, while modulating ribosome function and protein synthesis. It inhibits tumor growth and can be utilized in both in vivo and in vitro studies of gastric cancer.

Taraxerol acetate exhibits significant antiviral activity against herpes simplex virus type II, while exerting comparatively weaker effects on cell cycle arrest and apoptosis in AGS gastric cancer cells than taraxerol. Taraxerol acetate is a bioactive triterpene constituent of Anoectochilus roxburghiana, where its contribution to the plant’s antidiabetic activity is mechanistically associated with protein tyrosine phosphatase 1B (PTP1B) inhibition alongside betulin and betulinic acid, highlighting its relevance for antiviral, metabolic disease, and natural product pharmacology research.

Ibuprofen Lysine (Neoprofen) is a non-steroidal anti-inflammatory drug.

Anticanceragent 235 (Compound 49) functions as a modulator of the PI3K/AKT/mTOR signaling pathway, enhancing reactive oxygen species (ROS) production and reducing mitochondrial membrane potential, thereby inhibiting the proliferation of cancer cell lines HCT116, Caco-2, AGS, and SMMC-772 with IC50 values ranging from 0.35 to 26.9 μM. Additionally, it induces apoptosis and causes cell cycle arrest at the G2/M phase in HCT-116 cells.

AGS-67E is a CD37-targeted antibody-drug conjugate (ADC) consisting of a humanized mAb conjugated to MMAE. It binds specifically to CD37 on lymphoma cells and releases the toxin upon internalization, inducing apoptosis.

AGS-009 is a humanized monoclonal neutralizing antibody that targets IFN-α. It significantly reduces the number of activated lymphocytes (e.g., CD4+ and CD8+ T cells as well as B cells) in a SIV-infected rhesus monkey model. AGS-009 is applicable to research on autoimmune diseases such as systemic lupus erythematosus (SLE) and HIV infection.

Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a human antibody expressed in CHO cells, designed to target ENPP3/CD203c, widely applied in research and experiments in the field of life sciences.

AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3 (also known as CD203c). This product consists of a humanized IgG1 monoclonal antibody against ENPP3 conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF) via a non-cleavable linker. AGS-16C3F functions by specifically binding to ENPP3 on the surface of tumor cells, undergoing internalization, and releasing MMAF intracellularly to induce cell cycle arrest and apoptosis. It exhibits potent anti-tumor and anti-proliferative activity in ENPP3-expressing metastatic renal cell carcinoma (mRCC) and systemic mastocytosis.

KRAS G12D-IN-35 (example 7) is a potent, orally active inhibitor of KRAS G12D. It effectively suppresses p-ERK in AGS cells and significantly inhibits the proliferation of various KRAS G12D mutant cancer cell lines. Additionally, KRAS G12D-IN-35 reduces tumor growth in HPAC and GP2D mouse models. This compound is applicable for cancer research, including studies on pancreatic and colorectal cancer.

Tetracosane (Standard) is a reference standard for tetracosane, suitable for quantitative analysis, quality control, and biochemical experiments. Tetracosane is a natural product capable of inducing apoptosis in HT-29, MDA-MB-231, and AGS cells.

3-Hydroxymycophenolic acid (Compound 5) is a microbial transformation product of Mycophenolic acid derived from Cunninghamella echinulata. It exhibits relatively low cytotoxicity toward AGS cells and fibroblasts. 3-Hydroxymycophenolic acid can be utilized in research on immune-mediated kidney diseases.

Pyracrenic acid is a potent elastase inhibitor with an IC50 value of 1.5 mg/mL. Pyracrenic acid shows DPPH radical scavenging activity. It also shows significant cytotoxic activities against human cancer cells COLO 205 and AGS.